Your Health Questions
Answered by Professionals

Most bipolar disability benefit denials happen due to missing medical and functional evidence, not because you do not qualify, with common pitfalls like inconsistent treatment, vague notes, limited proof of work limitations, and unexplained gaps that make it appear symptoms are controlled. New medical steps to qualify include consistent psychiatric care that documents episodes and side effects, a detailed RFC from your clinician, tracking mood and attendance, submitting hospitalization or crisis records, documenting co occurring conditions, and appealing on time. There are several factors to consider. See below for the complete checklist, SSA approval targets, and mistakes to avoid that could change your next treatment and appeal strategy.

There are several factors to consider: depression is biologically diverse, about one-third of people do not respond to a first antidepressant, and medical research volunteers are driving new science by enabling trials of rapid-acting medicines like ketamine-based options, brain stimulation such as TMS, and personalized tools that match treatments to biology. If your meds are not working, do not stop suddenly and speak with your clinician about dose changes, combinations, or clinical trials; for safety details, practical next steps, and a symptom check that could guide your plan, see below.

If Entyvio is losing effectiveness, current guidance supports transitioning to an oral JAK inhibitor such as upadacitinib or tofacitinib, using a protocol that confirms active inflammation, screens for risks and needed vaccines, uses minimal or no washout, starts induction dosing, and monitors closely for 8 to 12 weeks. There are several factors to consider, including rapid benefits and steroid-sparing potential balanced against infection, shingles, lipid changes, clots, and cardiovascular risks in higher‑risk patients. See below for step-by-step timing, testing checklists, who should avoid JAK inhibitors, and urgent warning signs that could change your next steps.

Feeling physically drained yet mentally wired can signal a bipolar mixed state, where depressive and manic or hypomanic symptoms happen together and increase the risk of impulsive behavior and suicidal thoughts. There are several factors to consider. See below to understand more, including how to track symptoms, use a screening tool, and talk with a clinician about mood stabilizers, atypical antipsychotics, therapy, sleep and substance habits, and when to seek urgent help.

UC J-pouch alternatives are increasingly common, from advanced biologic and small-molecule medicines to treatment optimization with second opinions, access to clinical trials, and the option of a permanent ileostomy, with lifestyle changes used as supportive care. There are several factors to consider, since severe or complicated disease may still require surgery; see below for the key risks and benefits, red flags that need urgent care, and the specific questions and next steps to discuss with your gastroenterologist.

Humira can stop working due to primary non-response or secondary loss of response from anti-drug antibodies, low drug levels, a shift to non-TNF inflammation, or symptoms not driven by active inflammation. The medical next steps are to confirm active disease and drug levels with CRP, fecal calprotectin, therapeutic drug monitoring, and sometimes colonoscopy, then either optimize Humira or add an immunomodulator, switch to another anti-TNF, or move to a different class such as vedolizumab, ustekinumab, IL-23 inhibitors, or JAK inhibitors, with surgery considered in select cases. There are several factors to consider. See below to understand more.

After Remicade and Humira stop working for ulcerative colitis or Crohn’s, there are still medically approved paths to remission. Options include gut-selective integrin blockade like vedolizumab, IL-23 or IL-12/23 inhibitors like risankizumab, mirikizumab and ustekinumab, oral JAK inhibitors like upadacitinib and tofacitinib, S1P modulators like ozanimod, plus combination therapy or clinical trials. There are several factors to consider, such as confirming true failure with drug levels and inflammation testing, using a treat-to-target plan, and knowing when urgent care or surgery is appropriate, so see the complete details below to guide your next steps.

Anti-TNF failure in Crohn’s is common and often due to antibodies, low drug levels, or non-TNF inflammatory pathways, so first confirm active inflammation and check trough levels and antibodies before switching. Trial-backed next steps include vedolizumab, ustekinumab, risankizumab, and upadacitinib, with clinical trials available if standard options are not enough. There are several factors to consider, including when strictures may need surgery, which safety checks to do, and urgent red flags. For the complete, step-by-step guidance to choose your best next move with your gastroenterologist, see below.

Failing second-line IBD therapy often has fixable causes, including low drug levels or antibodies, more aggressive or stricturing disease, non-inflammatory mimics like IBS or bile acid diarrhea, and modifiable factors such as missed doses, NSAIDs, infections, or smoking. Next steps typically include confirming true inflammation, therapeutic drug monitoring, dose optimization or combination therapy, switching within or across drug classes, considering trials, and surgical evaluation when needed; there are several factors to consider, and important red flags and decision points are detailed below.

IBD urgency at work is real, driven by active inflammation, a hypersensitive bowel, and stress; evidence-based fixes include optimizing medical therapy (often with rectal treatments), setting predictable morning and eating routines, using antidiarrheals only with doctor guidance, practicing brief calming techniques, and arranging reasonable workplace accommodations. There are several factors to consider, including red flags like bleeding, fever, severe pain, or rapid worsening that need prompt medical care. See the complete guidance below for key details that could shape your next steps and help you feel more in control at your desk.

Most bipolar crisis plans fail because they are vague, start too late, rely only on your insight, skip doctor-approved medication protocols, and are not reviewed; a stronger plan uses specific early warning signs, stepwise actions, pre-approved med changes, strict sleep protection, financial safeguards, and a named support team. New medical steps now emphasize data-based mood and sleep tracking, rapid access appointments, medication adherence support, and screening for coexisting conditions, plus clear triggers for urgent care; there are several factors to consider, and key details that could change your next steps are outlined below.

Confusion, brain fog, or personality changes in people with liver disease can signal hepatic encephalopathy, a serious but treatable buildup of toxins like ammonia that affects the brain. Prompt treatment with lactulose and often rifaximin, plus fixing triggers like infection, constipation, dehydration, bleeding, or sedating meds, can reverse symptoms, but severe sleepiness, disorientation, vomiting blood, or black stools need emergency care. There are several factors to consider. See below for medically approved steps, warning signs, triggers to address, and urgent next actions that could change your care plan.

When a perianal fistula from Crohn’s keeps draining or recurring despite antibiotics, biologics, setons, or surgery, clinical trials can offer access to newer options such as next generation biologics, stem cell therapies, and targeted injections, with specialist oversight and structured safety monitoring. There are several factors to consider. See below for key details on eligibility, risks, visit schedules, what happens to your current meds, urgent red flags, and the exact questions to ask your IBD team to choose the right next step.

Many antidepressants can lead to weight gain by increasing appetite, slowing metabolism, or causing fatigue, but newer depression drugs that don't cause weight gain, such as bupropion, vortioxetine, vilazodone, and esketamine, may better protect metabolic health. Do not stop medication on your own; track changes and speak with your doctor about switching, dose adjustments, and metabolic labs. There are several factors to consider, including other medical causes and practical offset strategies; see below for details that could affect your next steps.

A racing or pounding heartbeat after taking amphetamine is a common, expected stimulant effect caused by sympathetic activation that raises norepinephrine, heart rate, and blood pressure; in most healthy people on prescribed doses it is mild and manageable. There are several factors to consider. See below to understand more, including red flags that need urgent care such as chest pain, fainting, severe shortness of breath, or a resting heart rate over 120 to 130, and medically approved next steps like reviewing your dose, avoiding other stimulants, staying hydrated, monitoring your pulse, and speaking with your prescriber rather than stopping the medication on your own.

A racing or pounding heart while taking phentermine is common because this stimulant activates the fight or flight system by releasing norepinephrine and adrenaline, which can raise heart rate and blood pressure; for some this is mild and short lived, but for others it may signal a stronger or unsafe reaction. Check your pulse, avoid caffeine and other stimulants, hydrate, and contact your prescriber about dose changes or testing, but seek emergency care for chest pain, shortness of breath, fainting, or a sustained resting rate over 120. There are several factors to consider, including drug interactions, personal risk conditions, and when to stop or switch medicines, so see the complete guidance below to choose the safest next steps.

High calprotectin while you feel okay on meds often means silent gut inflammation that still raises your risk of relapse, bowel damage, hospitalization, and increased colorectal cancer risk in long-standing ulcerative colitis. Next steps usually include repeating calprotectin, checking biologic drug levels and antibodies, ruling out infection, and considering colonoscopy or medication optimization; there are several factors to consider that can change your plan, so see the complete guidance below.

Depression is a multisystem condition that can leave the brain feeling stuck due to changes in neurotransmitters, stress hormones, mood circuits, inflammation, sleep, and reduced neuroplasticity. The strongest results come from integrative care that pairs medical treatments like medication, evidence based therapy, and options such as TMS, ketamine, or ECT with holistic foundations like sleep repair, movement, nutrition, gut health, and trauma work, with lifestyle plus therapy often enough for mild cases and medication essential for severe. There are several factors to consider. See below to understand more, including when to seek urgent help, why treatment may stall, which labs to check, and the newest protocols like personalized psychiatry, anti inflammatory and microbiome strategies, digital CBT, and a practical stepwise plan to guide your next steps with your clinician.

Spravato without insurance typically costs $600 to $900 per dose and about $1,000 to $1,500+ per supervised treatment session, adding up to roughly $8,000 to $12,000 for the first month and $2,000 to $5,000+ per month for maintenance. There are several factors to consider, including required in-clinic monitoring, treatment frequency, risks, eligibility for treatment-resistant depression, and possible assistance programs or alternatives. See below for important details that could change your next medical steps.

If Humira is no longer controlling your Crohn’s, first confirm true inflammation and check Humira drug and antibody levels, since adjusting the dose or adding an immunomodulator may restore benefit. If failure is confirmed, many do well by switching to Stelara or Skyrizi, with Entyvio, Rinvoq, or sometimes another anti-TNF as alternatives, but the right choice depends on why Humira failed, disease features, and safety considerations; see below for key details that can change your next steps.

When IBD meds stop working, there are several factors and proven next steps to consider: confirm active inflammation and drug levels, optimize current therapy, switch to another biologic class or to small molecules, and consider surgery when indicated. See details below on how doctors decide and what to do next. Stem cell therapy looks promising but is currently limited mainly to mesenchymal stem cells for complex perianal Crohn’s fistulas in some countries, while systemic transplants remain experimental and higher risk, with caution advised about unregulated clinics. For eligibility, safety, and alternatives that could change your next steps, review the complete guidance below.

If your IBD is not improving, IL-23 blockers may be the critical next step because they precisely target a key inflammatory pathway, often work even after anti-TNF failure, promote mucosal healing, and can help you achieve longer steroid-free remission. There are several factors to consider. See below for who might be a candidate, potential side effects and infection screening, and the key questions to discuss with your doctor that could shape your next steps.

Persistent rectal bleeding in IBD usually means your colon has not fully healed and inflammation is still active, often due to suboptimal or mismatched therapy, stubborn rectal involvement that needs topical treatment, or added issues like C. difficile, hemorrhoids, or fissures. There are several factors to consider; see below to understand more. New medical steps include treat-to-target care with biomarker and endoscopic goals, therapeutic drug monitoring, optimizing or switching biologics or JAK inhibitors, adding rectal therapies, and considering surgery if severe, plus knowing when to seek emergency care; key next-step details are outlined below.

If your IBS meds are not working, first confirm the diagnosis and absence of alarm symptoms, then bring a clear record of past treatments and ask your GI directly about ethically reviewed clinical trials, including eligibility, phase, risks, placebo, and time commitment. There are several factors to consider, including alternatives like dietitian-guided therapy, gut directed CBT, hypnotherapy, pelvic floor therapy, and adjusted neuromodulators, plus urgent symptoms that need immediate care, so see the complete guidance below to choose next steps.

If your IBS treatments are not working, Gastroenterology clinical trials can provide monitored access to innovative therapies and may be a proactive next step. There are several factors to consider; see below to understand more. The full guide below covers why standard options can fail, when and how trials are safe and appropriate, urgent red flags to watch for, and the key questions and logistics to review with your doctor.

There are several factors to consider if IBS treatments keep failing. True IBS is noninflammatory, so next-gen biologics are not standard care, but they become appropriate when tests show inflammation or your diagnosis shifts to IBD. See the complete guidance below for the key red flags, the labs and procedures to confirm inflammation, how biologics can improve outcomes in confirmed IBD, and the specific questions to ask your doctor about next steps.

IBS treatments can seem to resist medications because IBS is a gut brain interaction disorder with shifting subtypes, heightened nerve sensitivity, microbiome changes, and overlapping conditions, so a one-size plan often misses the mark; there are several factors to consider, and the details on reassessing your subtype, nonmedication strategies, and red flag symptoms are outlined below. Participating in medical research can provide supervised access to emerging therapies and help move precision IBS care forward when standard options fail; for how to find trials, what participation involves, and practical next steps to take with your clinician, see the complete answer below.

Secondary loss of response to adalimumab means it worked at first but symptoms have returned; common reasons include anti-drug antibodies, low drug levels, true disease progression, or noninflammatory lookalikes. Do not stop the medication on your own; your specialist can use therapeutic drug monitoring and objective inflammation tests to guide dose or interval increases, adding an immunomodulator, or switching to another anti-TNF or a different class like vedolizumab, ustekinumab, or JAK inhibitors. There are several factors to consider that can change your next steps, including warning signs that need urgent care, so see the complete guidance below.

There are several factors to consider. Creasing after Dysport rarely means failure; common reasons include normal movement, static wrinkles Dysport cannot erase, the treatment not yet fully active for up to 14 days, conservative dosing or strong muscles, differences in spread or faster metabolism, and rarely antibody resistance; see below for details and when to seek urgent care. Next steps include waiting the full 14 days, booking a 2 week follow up for touch ups or dose placement adjustments, and considering complementary options like fillers, lasers, or skincare, plus a symptom check if skin changes look abnormal; full guidance on timelines, options, and red flags is outlined below.

There are several factors to consider if your Entyvio benefits seem to be fading; anti-vedolizumab antibodies can form but are relatively uncommon at about 3 to 5 percent, and therapeutic drug monitoring can confirm whether low drug levels or antibodies are the cause. Depending on results, doctors may increase dosing frequency, selectively add an immunomodulator, or switch to another class, and you should not stop without medical guidance; see below for the specific tests, red flags that need urgent care, and other conditions to rule out that could change your next steps.